Questions and answers on PARP inhibitor use in somatic BRCA–mutated breast cancers
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Nadine Tung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Risk and Prevention Program and Breast Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Breast Neoplasms, Mutation, BRCA1 Protein. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Individuals with pathogenic variants in the BRCA1 or BRCA2 genes have an increased risk of developing breast, ovarian, pancreatic, and prostate cancers. BRCA variants can be of germline origin (ie, inherited) or arise spontaneously during tumor development (ie, somatic). Germline BRCA mutation status is determined by analyzing DNA from nontumor cells in blood or saliva. Tumor BRCA tests detect both germline and somatic BRCA mutations in tumor DNA, and somatic BRCA mutation status is determined when the tumor BRCA test is positive and the germline BRCA test is negative. BRCA1/BRCA2 inactivation results in homologous recombination deficiency, which sensitizes tumor cells with BRCA mutation to poly(ADP-ribose) polymerase (PARP) inhibitors. Thus, timely determination of BRCA status in patients with cancer can help guide optimal disease management. PARP inhibitors are approved across a range of treatment settings for several tumor types, as monotherapy or in combination, as well as in biomarker selected and unselected populations. For patients with human epidermal growth factor receptor 2-negative breast cancer and germline BRCA mutation (United States, European Union, and other markets) or germline or somatic BRCA mutation (Japan), PARP inhibitors are approved in early adjuvant (olaparib) and metastatic (olaparib, talazoparib) settings. Emerging evidence now suggests possible biological similarities in breast tumors with germline BRCA mutation and somatic BRCA mutation, with preclinical and translational data demonstrating that both can result in high levels of biallelic inactivation, homologous recombination deficiency phenotypes, and PARP inhibitor sensitivity. There is also evidence from clinical trials demonstrating the benefit of PARP inhibitor therapy in patients with somatic BRCA–mutated breast cancer, suggesting that the inclusion criteria of more trials should be expanded to include patients with somatic BRCA mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Risk and Prevention Program and Breast Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
- The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
- Department of Pathology and Laboratory Medicine, European Institute of Oncology IRCCS, Milan, Italy.
- Maryland Oncology Hematology, Annapolis, MD, United States.
- Oncology R&D, Translational Medicine, AstraZeneca, Cambridge, United Kingdom.
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
ORCID-Profile: Nadine Tung, Robert L Hollis, Carol Tweed, Natalia Lukashchuk, Michael Birrer
Förderung
- AstraZeneca
- Merck Sharp & Dohme LLC
Zitieren
APA
Tung, N., Hollis, R. L., Viale, G., Tweed, C., Lukashchuk, N., & Birrer, M. (2026). Questions and answers on PARP inhibitor use in somatic BRCA–mutated breast cancers. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf205
Vancouver
Tung N, Hollis RL, Viale G, Tweed C, Lukashchuk N, Birrer M. Questions and answers on PARP inhibitor use in somatic BRCA–mutated breast cancers. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf205
BibTeX
@article{Tung2026,
author = {Tung, Nadine and Hollis, Robert L and Viale, Giuseppe and Tweed, Carol and Lukashchuk, Natalia and Birrer, Michael},
title = {Questions and answers on PARP inhibitor use in somatic BRCA–mutated breast cancers},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf205}
}
EUVIMED